These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 25114133)

  • 1. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors.
    Vargiu AV; Ruggerone P; Opperman TJ; Nguyen ST; Nikaido H
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6224-34. PubMed ID: 25114133
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular basis for inhibition of AcrB multidrug efflux pump by novel and powerful pyranopyridine derivatives.
    Sjuts H; Vargiu AV; Kwasny SM; Nguyen ST; Kim HS; Ding X; Ornik AR; Ruggerone P; Bowlin TL; Nikaido H; Pos KM; Opperman TJ
    Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3509-14. PubMed ID: 26976576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic analysis of the inhibition of the drug efflux protein AcrB using surface plasmon resonance.
    Mowla R; Wang Y; Ma S; Venter H
    Biochim Biophys Acta Biomembr; 2018 Apr; 1860(4):878-886. PubMed ID: 28890187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chlorpromazine and Amitriptyline Are Substrates and Inhibitors of the AcrB Multidrug Efflux Pump.
    Grimsey EM; Fais C; Marshall RL; Ricci V; Ciusa ML; Stone JW; Ivens A; Malloci G; Ruggerone P; Vargiu AV; Piddock LJV
    mBio; 2020 Jun; 11(3):. PubMed ID: 32487753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a novel pyranopyridine inhibitor of the AcrAB efflux pump of Escherichia coli.
    Opperman TJ; Kwasny SM; Kim HS; Nguyen ST; Houseweart C; D'Souza S; Walker GC; Peet NP; Nikaido H; Bowlin TL
    Antimicrob Agents Chemother; 2014; 58(2):722-33. PubMed ID: 24247144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-activity relationships of a novel pyranopyridine series of Gram-negative bacterial efflux pump inhibitors.
    Nguyen ST; Kwasny SM; Ding X; Cardinale SC; McCarthy CT; Kim HS; Nikaido H; Peet NP; Williams JD; Bowlin TL; Opperman TJ
    Bioorg Med Chem; 2015 May; 23(9):2024-34. PubMed ID: 25818767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyridylpiperazine-based allosteric inhibitors of RND-type multidrug efflux pumps.
    Plé C; Tam HK; Vieira Da Cruz A; Compagne N; Jiménez-Castellanos JC; Müller RT; Pradel E; Foong WE; Malloci G; Ballée A; Kirchner MA; Moshfegh P; Herledan A; Herrmann A; Deprez B; Willand N; Vargiu AV; Pos KM; Flipo M; Hartkoorn RC
    Nat Commun; 2022 Jan; 13(1):115. PubMed ID: 35013254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aminoacyl β-naphthylamides as substrates and modulators of AcrB multidrug efflux pump.
    Kinana AD; Vargiu AV; May T; Nikaido H
    Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1405-10. PubMed ID: 26787896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of the Drug Binding Pocket Defects of the AcrB Multidrug Efflux Pump Protein of Escherichia coli.
    Soparkar K; Kinana AD; Weeks JW; Morrison KD; Nikaido H; Misra R
    J Bacteriol; 2015 Oct; 197(20):3255-64. PubMed ID: 26240069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multidrug binding properties of the AcrB efflux pump characterized by molecular dynamics simulations.
    Vargiu AV; Nikaido H
    Proc Natl Acad Sci U S A; 2012 Dec; 109(50):20637-42. PubMed ID: 23175790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of a novel series of pyranopyridine RND efflux pump inhibitors.
    Aron Z; Opperman TJ
    Curr Opin Microbiol; 2016 Oct; 33():1-6. PubMed ID: 27232955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Random mutagenesis of the multidrug transporter AcrB from Escherichia coli for identification of putative target residues of efflux pump inhibitors.
    Schuster S; Kohler S; Buck A; Dambacher C; König A; Bohnert JA; Kern WV
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6870-8. PubMed ID: 25182653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative reassessment of AcrB efflux inhibitors reveals differential impact of specific pump mutations on the activity of potent compounds.
    Schuster S; Vavra M; Wirth DAN; Kern WV
    Microbiol Spectr; 2024 Feb; 12(2):e0304523. PubMed ID: 38170977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Reserpine Is the New Addition into the Repertoire of AcrB Efflux Pump Inhibitors].
    Shaheen A; Afridi WA; Mahboob S; Sana M; Zeeshan N; Ismat F; Mirza O; Iqbal M; Rahman M
    Mol Biol (Mosk); 2019; 53(4):674-684. PubMed ID: 31397441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and synthesis of novel 4-substituted quinazoline-2-carboxamide derivatives targeting AcrB to reverse the bacterial multidrug resistance.
    Gu X; Pisoni LA; Wang Y; Song D; Sykes MJ; Qin Y; Semple SJ; Polyak SW; Venter H; Ma S
    Bioorg Chem; 2020 Dec; 105():104394. PubMed ID: 33120321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a series of 2-napthamide derivatives as inhibitors of the drug efflux pump AcrB for the reversal of antimicrobial resistance.
    Wang Y; Mowla R; Guo L; Ogunniyi AD; Rahman T; De Barros Lopes MA; Ma S; Venter H
    Bioorg Med Chem Lett; 2017 Feb; 27(4):733-739. PubMed ID: 28129976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some ligands enhance the efflux of other ligands by the Escherichia coli multidrug pump AcrB.
    Kinana AD; Vargiu AV; Nikaido H
    Biochemistry; 2013 Nov; 52(46):8342-51. PubMed ID: 24205856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of substituted piperazines able to reverse MDR in Escherichia coli strains overexpressing resistance-nodulation-cell division (RND) efflux pumps.
    Casalone E; Vignolini T; Braconi L; Gardini L; Capitanio M; Pavone FS; Giovannelli L; Dei S; Teodori E
    J Antimicrob Chemother; 2022 Feb; 77(2):413-424. PubMed ID: 34747445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of site-directed mutations in multidrug efflux pump AcrB examined by quantitative efflux assays.
    Kinana AD; Vargiu AV; Nikaido H
    Biochem Biophys Res Commun; 2016 Nov; 480(4):552-557. PubMed ID: 27789287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for the inhibition of bacterial multidrug exporters.
    Nakashima R; Sakurai K; Yamasaki S; Hayashi K; Nagata C; Hoshino K; Onodera Y; Nishino K; Yamaguchi A
    Nature; 2013 Aug; 500(7460):102-6. PubMed ID: 23812586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.